Amlodipine,valsartan And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 33342-283

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Amlodipine, Valsartan And Hydrochlorothiazide (NDC 33342-283). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

283-30s (283 30s Count)

Packaging label for Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP, with strength 5 mg/160 mg/12.5 mg. The label indicates 30 film-coated tablets for oral use, manufactured by Macleods Pharmaceuticals Limited. The label includes dosage information, storage conditions, and a barcode.*

FDA Label Image

284-30s (284 30s Count)

Label for Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP, film-coated oral tablets in strength 10 mg/160 mg/12.5 mg. The label indicates 30 tablets per bottle, manufactured by Macleods Pharmaceuticals Limited. Storage instructions and dosage information cautions are included, along with barcodes and product codes.*

FDA Label Image

285-30s (285 30s Count)

Label for Amlodipine, Valsartan and Hydrochlorothiazide Tablets USP, film-coated, with strengths 5 mg amlodipine, 160 mg valsartan, and 25 mg hydrochlorothiazide. The label also includes storage instructions, manufacturer details (Macleods Pharmaceuticals Ltd., India), and package quantity of 30 tablets. The label features a barcode and a cautions section.*

FDA Label Image

286-30s (286 30s Count)

Label for amlodipine, valsartan and hydrochlorothiazide tablets USP, film coated, oral dosage form. This package contains 30 tablets with a strength of 10 mg amlodipine, 160 mg valsartan, and 25 mg hydrochlorothiazide. Manufactured by Macleods Pharmaceuticals Limited and Macleods Pharma USA. Storage instructions and usual dosage are noted on the label.*

FDA Label Image

287-100s-carton (287 100s Carton)

Packaging label for Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP 10 mg/320 mg/25 mg, film coated oral tablets. The label indicates a 100 tablet count (10 x 10 unit-dose) and identification with NDC 33342-287-12. Manufactured by Macleods Pharmaceuticals Limited for Macleods Pharma USA, Inc. Storage and usage details are provided on the label along with a barcode.*

FDA Label Image

287-30s (287 30s Count)

Label for Amlodipine, Valsartan and Hydrochlorothiazide Tablets, USP, film coated, with strength 10 mg/320 mg/25 mg. The label includes the product name, dosage form, strength, manufacturer as Macleods Pharma USA, Inc., storage instructions, and package quantity of 30 tablets. National Drug Code (NDC) 33342-287-07 is visible along with a barcode.*

FDA Label Image

287-90s (287 90s Count)

Label for amlodipine, valsartan, and hydrochlorothiazide tablets USP, 10 mg/320 mg/25 mg strength, film-coated tablets. The label indicates a quantity of 90 tablets, manufactured by Macleods Pharmaceuticals Limited. It includes storage instructions, dosage reference, and barcodes.*

FDA Label Image

Amlodipine-struc (Amlodipine)

Chemical structure diagram of the active ingredients amlodipine, valsartan, and hydrochlorothiazide, showing molecular components and bonding arrangements relevant to these compounds.*

FDA Label Image

Figure-1 (Figure 1)

A bar graph comparing the effects of different amlodipine, valsartan, and hydrochlorothiazide formulations on diastolic and systolic blood pressure (BP). It shows four groups: HCTZ/Aml 25/10, Val/HCTZ 320/25, Aml/Val 10/320, and Aml/Val/HCTZ 10/320/25, with corresponding reductions in diastolic and systolic BP indicated by bars and labeled numeric values.*

FDA Label Image

Figure-2 (Figure 2)

A line graph displaying mean sitting diastolic blood pressure (DBP) in mmHg over 8 weeks for four treatment groups involving combinations of amlodipine (Aml), valsartan (Val), and hydrochlorothiazide (HCTZ) at various dosages. The x-axis shows weeks from 0 to 8, while the y-axis ranges from 80 to 110 mmHg.*

FDA Label Image

Figure-3 (Figure 3)

Line graph depicting mean sitting systolic blood pressure (SBP) in mmHg over an 8-week period for different treatments: Amlodipine/valsartan/hydrochlorothiazide 10/320/25 mg, valsartan/hydrochlorothiazide 320/25 mg, amlodipine/valsartan 10/320 mg, and hydrochlorothiazide/amlodipine 25/10 mg. The graph shows trends in SBP reduction for each treatment group across time.*

FDA Label Image

Figure-4 (Figure 4)

A line graph depicting mean ambulatory diastolic blood pressure (DBP) in mmHg measured over 24 hours after dosing. The x-axis represents hours after dosing (0 to 24), and the y-axis shows mean ambulatory DBP ranging from 50 to 100 mmHg. Four treatment groups are compared: Aml/Val/HCTZ 10/320/25 mg, Aml/Val 10/320 mg, Val/HCTZ 320/25 mg, and HCTZ/Aml 25/10 mg, each represented by distinct line styles and markers.*

FDA Label Image

Figure-5 (Figure 5)

A line graph showing mean ambulatory systolic blood pressure (SBP) in mmHg versus hours after dosing (0 to 24 hours). It compares four treatments: Aml/Val/HCTZ 10/320/25 mg, Aml/Val 10/320 mg, Val/HCTZ 320/25 mg, and HCTZ/Aml 25/10 mg. Each treatment is represented by a different symbol and line style, illustrating SBP changes over 24 hours.*

FDA Label Image

Hctz-struc (Hydrochlorothiazide)

Chemical structure of hydrochlorothiazide, showing its molecular framework with chlorine, sulfonamide, and other characteristic functional groups.*

FDA Label Image

Valsartan-struc (Valsartan)

Chemical structure diagram of valsartan, one of the active ingredients in the amlodipine, valsartan and hydrochlorothiazide combination tablet.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.